M06-890: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ST

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究的目的是确定ABT-874在中重度慢性斑块状银屑病患者中的安全性和有效性。将研究两种不同的剂量，并与安慰剂进行比较。 安慰剂是一种非活性物质，就像活性药物一样，但不含ABT-874。这项研究将观察ABT-874与安慰剂相比在52周内治疗银屑病的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety and effectiveness of ABT-874 in patients with moderate to severe chronic plaque psoriasis. Two different doses will be studied and compared to placebo. A placebo is an inactive substance that is given just like the active drug, but does not contain ABT-874. This study will look at how well ABT-874 treats psoriasis compared to Placebo over a 52-week period.